Tag Archives: Merck

CETP Inhibitors: Blockbusters that Never Ran?

The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, leadership, R&D, Technology | Also tagged , , , , , , | Leave a comment

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, leadership, Market Access, pricing, R&D, Strategy | Also tagged , , , | Leave a comment

Merck Gets to the Heart of the Matter

Merck may have succeeded in making a molecule that increases “good cholesterol,” which is likely the only real breakthrough left in the anti-cholesterol and hypertension market. It has long been known that elevated LDL cholesterol and reduced HDL cholesterol are major risk factors for developing cardiovascular disease. And while much ado has been made about […]
Posted in News, Strategy | Also tagged , | 1 Comment

Merck to Close Eight Plants

Image by Getty Images via @daylife Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.” Taking a page out of […]
Posted in Strategy | Also tagged , , , , , , | 3 Comments

Abbott Shells Out $3.7 Billion for Piramal

In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, […]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta